Trial Search Results

Safety and Efficacy Study of Fostamatinib to Treat Immunoglobin A (IgA) Nephropathy

The purpose of this study is to determine whether fostamatinib is safe and effective in the treatment of IgA Nephropathy

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Rigel Pharmaceuticals

Stanford Investigator(s):


  • Drug: Fostamatinib 150 mg
  • Drug: Fostamatinib 100 mg
  • Drug: Placebo


Phase 2


Inclusion Criteria:

   - Renal biopsy findings consistent with IgA nephropathy

   - Treatment with an Angiotensin Converting Enzyme inhibitor (ACEi) and/or an Angiotensin
   II Receptor Blocker (ARB) for at least 90 days at the maximum approved (or tolerated)

   - Proteinuria > 1 gm/day at diagnosis of IgA nephropathy and Proteinuria > 0.50 gm/day
   at the second Screening Visit

   - Blood pressure controlled to ≤ 130/80 with angiotensin blockade with or without other
   anti-hypertensive agents

Exclusion Criteria:

   - Recent use of cyclophosphamide, mycophenolate mofetil, azathioprine, or Rituximab.

   - Use of > 15 mg/day prednisone (or other corticosteroid equivalent).

Ages Eligible for Study

18 Years - 70 Years

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Richard Lafayette, MD
Not Recruiting